Arboreal Bioinnovations raises Rs 230 crore Series A to scale functional ingredients

The Lucknow-based B2B functional-ingredients company has raised Rs 230 crore in a Series A co-led by Edelweiss Alternatives’ EAAA and Omnivore. Arboreal plans to expand manufacturing, R&D and commercialisation for food, beverage, nutraceutical and CPG customers.

— FiledThu, 30 Jul, 2026, 14:58 IST·First seen Thu, 30 Jul, 2026, 14:58 IST·Source Entrackr

What happened

Arboreal Bioinnovations raised Rs 230 crore in a Series A co-led by EAAA and Omnivore to expand manufacturing, R&D and commercialisation of functional

Key facts

  • Rs 230 crore
  • over $24 million
  • more than 1,100 B2B customers
  • Founded in May 2018

Why this matters

Arboreal’s funding-backed push into manufacturing, R&D and commercialisation makes it a more credible partnership, supply-chain or strategic-investment candidate for consumer-health and food companies seeking differentiated ingredients.

What to watch

  • Announcement of new plant capacity, commissioning timelines and utilisation targets.
  • Named customer wins, especially repeat contracts with large food, beverage, nutraceutical or CPG companies.
  • New ingredient launches with defined use cases such as protein, fibre, natural sweetening, flavour, preservation or wellness formulations.
  • Evidence of import substitution, export certifications or international distribution partnerships.
  • Gross-margin trends, working-capital needs and the pace of commercial revenue conversion after the funding round.
  • Follow-on funding, strategic investment or partnership activity from global ingredients companies.
  • Commission or expand manufacturing lines for high-margin functional ingredients and establish quality-control systems required by large FMCG and nutraceutical buyers.
  • Build application-development capabilities to co-create formulations with beverage, dairy, bakery, nutrition and supplement customers.
  • Convert pilots into multi-year supply agreements, prioritising anchor accounts that validate scale and improve capacity utilisation.
  • Use the Omnivore and Edelweiss networks to pursue export channels, contract manufacturing opportunities and future strategic partnerships.
  • Strengthen regulatory, traceability and claims-substantiation capabilities as customers demand clean-label, clinically supported and sustainably sourced ingredients.

Also reported by